Digoxin Administration: Indications and Method
For stable patients with heart failure in sinus rhythm, loading doses are generally not required—start with a single daily maintenance dose of 0.25 mg in adults with normal renal function, reducing to 0.125 mg or 0.0625 mg daily in elderly patients (>70 years), those with renal impairment, or low lean body mass. 1, 2, 3, 4
Primary Indications
Heart Failure with Reduced Ejection Fraction (HFrEF)
Atrial Fibrillation with Rapid Ventricular Rate (Class I Recommendation)
- Use digoxin to slow rapid ventricular rate in symptomatic HF patients with AF
- Indicated when resting heart rate >80 bpm or exercise rate >110-120 bpm
- Should be used in addition to, or prior to, beta-blocker therapy in patients with LVEF <40% 1, 2, 1
Sinus Rhythm (Class IIa Recommendation)
- Consider in patients with LVEF <40% and NYHA class II-IV symptoms
- Use only after optimization with ACEI/ARB, beta-blocker, and aldosterone antagonist
- Reduces hospitalizations for worsening HF but does not improve mortality 1, 2, 3
- The 2022 AHA/ACC/HFSA guidelines downgraded this to Class 2b, reflecting uncertainty about benefit in the era of modern GDMT 5, 6
Dosing Regimens
Initiation Without Loading Dose (Preferred for Stable Patients)
Standard Maintenance Dosing:
- Normal renal function, age <70 years: 0.25 mg once daily
- Elderly (>70 years) OR impaired renal function: 0.125 mg once daily
- Marked renal impairment: 0.0625 mg once daily or every other day 1, 2, 3, 4
Steady-state concentrations are achieved in approximately 5 half-lives (1-3 weeks depending on renal function) 4
Rapid Digitalization with Loading Dose (Rarely Needed)
When rapid digitalization is medically appropriate:
- Administer loading dose in divided portions over 6-8 hour intervals
- First dose: approximately half the total planned loading dose
- Typical total loading dose for 70 kg patient: 750-1250 mcg (0.75-1.25 mg) to achieve peak body stores of 8-12 mcg/kg
- Example: Initial 500-750 mcg, then additional 125-375 mcg doses at 6-8 hour intervals 4
Critical caveat: Loading doses are generally NOT required in stable HF patients and increase risk of toxicity 3, 4. Recent data from critically ill patients suggest loading doses >8 mcg/kg ideal body weight resulted in supratherapeutic levels 7.
Absolute Contraindications
- Second- or third-degree AV block (without permanent pacemaker)
- Pre-excitation syndromes (e.g., Wolff-Parkinson-White)
- Previous digoxin intolerance
- Sick sinus syndrome (use with extreme caution) 1, 2, 1
Therapeutic Drug Monitoring
Target serum digoxin concentration: 0.5-0.9 ng/mL (lower than historically recommended) 2, 3
- The traditional range of 0.8-2.0 ng/mL is outdated
- Concentrations ≥1.2 ng/mL associated with increased mortality risk 5, 6
- Check levels early during therapy in patients with normal renal function
- Sample timing: just before next dose, or at least 6-8 hours after last dose 4
- Regular monitoring not required once stable, but check when clinical response changes 2
Critical Drug Interactions Requiring Dose Reduction
The following medications increase digoxin levels and necessitate dose reduction:
- Amiodarone
- Verapamil, diltiazem
- Quinidine, propafenone
- Clarithromycin, erythromycin
- Itraconazole, cyclosporine
- Dronedarone 2, 3
Monitoring Requirements
Mandatory serial monitoring:
- Serum electrolytes (particularly potassium and magnesium)
- Renal function (creatinine/eGFR)
- Hypokalemia dramatically increases arrhythmia risk 1, 2
Signs of Toxicity
Cardiac: Sinoatrial/AV block, atrial and ventricular arrhythmias (especially with hypokalemia)
Non-cardiac: Confusion, nausea, anorexia, visual disturbances (color vision changes) 1, 2, 1
Management: Digoxin-specific Fab antibody fragments for ventricular arrhythmias from toxicity 1, 2
Important Clinical Pearls
- Beta-blockers are superior to digoxin for long-term rate control in AF with HF, either alone or combined with digoxin 1, 2
- Digoxin provides no benefit in heart failure with preserved ejection fraction (HFpEF) 2
- In modern practice with optimized GDMT (ARNI, SGLT2i, etc.), digoxin's role is increasingly limited to symptomatic patients who remain inadequately controlled 5, 6
- Doses >0.25 mg daily are rarely needed and increase toxicity risk without additional benefit 3, 8